AG
DFTX

Algert Global’s Definium Therapeutics DFTX Stock Holding History

Algert Global’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3M Buy
+63,700
New +$1.57M 0.04% 719
2025
Q2 		– Sell
-24,770
Closed -$145K – 1274
2025
Q1 		$145K Buy
+24,770
New +$177K ﹤0.01% 1108

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Algert Global's DFTX Position: Q2 2026 in Review

Algert Global opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 63,700 shares worth $3M. The stake represents 0.04% of the portfolio and ranks #719 among its holdings. This is a return to the name: Algert Global previously reported a position in DFTX as recently as Q1 2025.

Algert Global first reported a position in DFTX in Q1 2025 and has held it in 2 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Algert Global held 63,700 shares of Definium Therapeutics worth $3M as of Q2 2026.
  • Definium Therapeutics was a new Algert Global position in Q2 2026.
  • Definium Therapeutics made up 0.04% of Algert Global's portfolio in Q2 2026, its #719 holding.
  • Algert Global first reported a position in Definium Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.